UNASSIGNED: 23 Background: Few studies have examined costs of @entity5 care and we lack a clear understanding of cost trends. In this study, we examined longitudinal treatment- and @entity1 -related hospitalization costs within 5 years of diagnosis of @entity981 ( @entity981 ), the most common @entity5 in the United States. METHODS: We used data on N=555 @entity1 diagnosed with @entity981 from 1998 to 2013 identified through the Intermountain Healthcare System in UT. The majority of these @entity1 (>95%) were diagnosed and treated at the Primary @entity1 's Hospital (PCH) in Salt @entity17360 City, UT. PCH encompasses the largest coverage area in the continental U.S. served by a single @entity1 's hospital. We computed the average annual per @entity1 hospitalization cost (aggregate and by components such as room, care and nursing cost, pharmacy cost, therapy and diagnostics costs). We used the generalized estimating equations (GEE) regression framework to identify @entity1 characteristics (sex, age, race, rural/urban residence, insurance, high vs. standard risk, relapse, bone marrow transplant (BMT), and year of diagnosis) associated with hospital-related treatment costs (total cost per encounter). RESULTS: Annual average cost of per @entity1 hospitalization increased by 26% from 1998-2005 to 2006-2013. Most of this increase was driven by annual increases in room, care and nursing costs (increased by 29%) and pharmacy cost (increased by 79%). Our GEE models indicated the greatest costs among relapsed @entity1 (average difference (  ) = 15,507 vs. those without relapse), BMT @entity1 (  = 15,184 vs. no transplant) and @entity1 older than 10 years at diagnosis (  = 8,539 vs. @entity1 younger than 10 years at diagnosis). Publically insured @entity1 had per encounter hospitalization costs that were greater (  = 931) than privately insured. CONCLUSIONS: Average annual cost of hospitalization for @entity981 care has increased over the past fifteen years. Management of room, care and nursing, and pharmacy costs need to be considered in efforts to address the cost burden. In addition, @entity1 -centered strategies to manage higher costs, such as better management of @entity1 who are older at diagnosis or publically insured, may be warranted.

Treatment-related costs of pediatric XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['pediatric cancer', 'childhood cancer'] @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children', 'patient'] @entity981 :: ('MESH:D054198', 'Disease') :: ['pediatric ALL', 'ALL', 'acute lymphoblastic leukemia'] @entity17360 :: ('83971', 'Species') :: ['Lake']
@entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukemia']
